Abstract
Peritoneal dissemination is a significant variable affecting long term survival of abdominal cancer patients. A generally accepted clinical point of view is that peritoneal dissemination is tantamount to distant organ metastases. This implies it to be a terminal condition. Current practice dictates that if peritoneal dissemination is observed intraoperatively, the curative therapeutic options are deferred and comprehensive systemic chemotherapy remains the only option with a dismal prognosis. The past few years have generated lot of interest in management of peritoneal carcinomatosis. Prof Paul Sugarbaker has researched, validated and fine-tuned the concept of cytoreductive surgery with peritonectomy procedure (Sugarbaker technique) and perioperative chemotherapy as HIPEC & EPIC. Recognition of a HIPEC centre is based on an infrastructure equipped with basic knowledge of the tumor biology, oncosurgical techniques, technical knowhow for HIPEC administration, intensive care unit etc. There are some aspects which need to be accorded special consideration. Comprehensive therapy of Cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is initiated with exploration and cytoreductive surgery and includes visceral resections and peritonectomy procedure when achieved optimally results in complete, visible resection of all cancer within the abdomen and pelvis. Subsequent to CRS, HIPEC forms an integral part of the surgical procedure. This approach involves conceptual changes in both the route and timing of chemotherapy administration. Patient selection is of utmost importance. The greatest impediment to lasting benefits from intraperitoneal chemotherapy remains an improper patient selection. Currently, there are four important clinical assessments of peritoneal metastasis that need to be used to select patients ie; histopathological type of tumour, radiological distribution of disease, peritoneal cancer index and completeness of cytoreduction. Patients undergoing HIPEC surgery face the usual physiological insults of a major surgery in addition to the thermal stress secondary to intraperitoneal administration of heated chemotherapy agent. A team approach of everyone involved in care of these patients is known to improve patient outcomes. It has also been observed that with the necessary preoperative & perioperative steps, the morbidity and mortality for this treatment can be brought down as comparable to any other major abdominal surgeries.
Similar content being viewed by others
References
Sugarbaker PH et al. (2013) Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: Textbook and video Atlas. PSOGI 1:1, 22
Gonza’lez-Moreno S (2006) Peritoneal surface oncology: a progress report. Eur J Surg Oncol 32:593–596
BM R, CM Z, RJ K, PH S, BM S (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J surg Pathol 19:1390–1408
CA C, EA B, Chang D, PH S (2006) Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 130:1654–1661
Stellar EP (1988) Comparison of four scoring methods for an intraperitoneal immunotherapy model. Erasmus University Rotterdam
Jacquet P, Jelinek JS, Chang D, Koslowe P, Sugarbaker PH (1995) Abdominal CT scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am College Surg 181:530–538
Yan TD, Haveric N, Carmignani P, Chang D, Sugarbaker PH (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 15:839–849
Koh JL, Tristan DY, Glenn D, et al. (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16:327–333
Portilla G, PH S, Chang D (1999) Second look surgery after cytoreductive and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 23:23–29
Berthet B, TA S, Chang D, PH S (1999) Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 35:413–419
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosisfrom colorectal cancer: A Multi-institutional study. J Clin Oncol 22:3284–3292
Stede SR, Maykel JA, Champagne IJ, Orangio GR (2014) Complexities in colorectal surgeries: Decision making & management. Springer, New York
Vashi PG, Gupta d, Lammersfeld CA, Braun DP, Popiel B (2013) The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. Nutrition Journal 12:118
Smeenk RM et al. (2007) Learning Curve of Combined Modality Treatment in Peritoneal Surface Disease. Br J Surg 94(11):1408–1414
Gonzalez-Moreno S et al. (2010) Hyperthermic Intraperitoneal Chemotherapy: Rationale and Technique World. J GastrointestOncol 2(2):68–75
Anaesthetic management in patients undergoing hyperthermic chemotherapy. Current opinion in Anaesthesiology 2012, Vol 25, issue 3, p 348–355
Rothfield K et al. (2012) Anesthesia Considerations during Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. SurgOncolClin N Am 21:533–541
Kanakoudis F et al. (1996) Anesthesia for intraperitoneal perfusion of hyperthermic chemotherapy. hemodynamic changes, oxygen consumption and delivery. Anaesthesia 51(11):1033–1036
Fleisher LA et al. ACC/AHA (2007) Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery executive summary Circulation 2007; 116(17):1971–1996
Raspe C et al. (2012) Anesthetic management in patients undergoinghyperthermic chemotherapy. CurrOpinAnaesthesiol 25(3):348–355
Owusu-Agyemang P et al. (2012) Anesthetic management andrenal function in pediatric patients undergoing cytoreductive surgery with continuoushyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. AnnSurgOncol 19(8):2652–2656
Gonzalez-Moreno S, Gonzalez-Bayon L, Ortega-Perez G (2012) Hyperthermic Intraperitoneal chemotherapy-methodology and safety considerations. Surg Oncol Clin N Am 21:543–557
Na¨slundAndre’asson S. (2011) Work environment in the operating room during cytoreductivesurgery and hyperthermic intraperitoneal chemotherapy: factors influencingthe choice of protective equipment. Digital Comprehensive Summariesof Uppsala Dissertations from the Faculty of Medicine 716. Uppsala (Sweden):ActaUniversitatisUpsaliensis p. 35–38
SN A’a et al. (2009) Peritonectomy with high voltage electrocautery generates higher levels of ultrafine smoke particles. Eur J SurgOncol 3:780–784
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ashvin, R., Nikhilesh, J. Preoperative Preparation and Patient Selection for Cytoreductive Surgery and HIPEC. Indian J Surg Oncol 7, 208–214 (2016). https://doi.org/10.1007/s13193-016-0514-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-016-0514-4